Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map
Calcified Tissue International · 2026
DOI: 10.1007/s00223-026-01608-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Calcified Tissue International, 2026. Verfasst von Dong-Ju Lim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Spine Division, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-Ro, Nowon-Gu, Seoul, 01757,…. Hauptthemen laut MEDLINE: Sarcopenia, Bone Density Conservation Agents, Osteoporosis, Muscle, Skeletal. Die Arbeit nennt 60 Literaturangaben.
Abstract (Originalsprache)
Anti-osteoporotic drugs are increasingly discussed as candidate dual bone-muscle therapies in osteosarcopenia, yet clinical claims often conflate biological plausibility, observational signals, and randomized efficacy. We conducted a source-verified scoping evidence map and translational review, updated through 25 July 2026 using PubMed/MEDLINE, Europe PMC, and citation tracking. Evidence was classified as primary randomized evidence, secondary randomized analysis, observational human evidence, mechanistic/preclinical rationale, or review-level context; quantitative pooling was avoided because no drug-outcome pair had a sufficiently homogeneous randomized evidence base. Denosumab has the most coherent translational rationale through RANKL/RANK/NF-kB signaling, but randomized long-term-care data were neutral for muscle mass, strength, and performance despite bone mineral density improvement. Long-term-care context may reduce anabolic reserve, but a drug-by-exercise interaction remains unproven. Early pamidronate data in severe pediatric burns support prevention of resorption-linked muscle catabolism rather than reversal of established age-related sarcopenia. Bisphosphonates and teriparatide have preclinical or secondary signals; romosozumab and abaloparatide lack direct clinical muscle-efficacy evidence. Nandrolone is retained only as a historical positive control. Future trials should distinguish prevention from reversal and use factorial or rigorously standardized exercise designs with prespecified strength, muscle-mass, physical-performance, and pathway endpoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Spine Division, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-Ro, Nowon-Gu, Seoul, 01757, Republic of Korea. scd25@paik.ac.kr.
- Department of Orthopedic Surgery, Spine Division, Sanggye Paik Hospital, Inje University College of Medicine, 1342 Dongil-Ro, Nowon-Gu, Seoul, 01757, Republic of Korea.
Zitieren
APA
Lim, D. J., & Kang, M. K. (2026). Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map. Calcified Tissue International. https://doi.org/10.1007/s00223-026-01608-5
Vancouver
Lim DJ, Kang MK. Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map. Calcified Tissue International. 2026. doi:10.1007/s00223-026-01608-5
BibTeX
@article{Lim2026,
author = {Lim, Dong-Ju and Kang, Min Kue},
title = {Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map},
journal = {Calcified Tissue International},
year = {2026},
doi = {10.1007/s00223-026-01608-5}
}
EUVIMED